{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T20:26:17Z","timestamp":1775852777522,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81803550"],"award-info":[{"award-number":["81803550"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.intimp.2022.109299","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T12:55:34Z","timestamp":1666011334000},"page":"109299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"PA","title":["Prophylaxis strategies containing high dose intravenous methotrexate on preventing CNS relapse for patients with diffuse large B-cell lymphoma at intermediate to high risk: A study based on 12 cohorts in the rituximab era"],"prefix":"10.1016","volume":"113","author":[{"given":"Nianhai","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianhe","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zili","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.intimp.2022.109299_b0005","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/ijc.28849","article-title":"Lymphoid neoplasm incidence by WHO subtype in Australia 1982\u20132006","volume":"135","author":"van Leeuwen","year":"2014","journal-title":"Int. J. Cancer"},{"issue":"20","key":"10.1016\/j.intimp.2022.109299_b0010","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.intimp.2022.109299_b0015","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1182\/bloodadvances.2020002421","article-title":"Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery","volume":"4","author":"Wilson","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.intimp.2022.109299_b0020","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1200\/GO.20.00422","article-title":"Real-World Data (RWD) on the 3-year follow-up outcomes of different CNS prophylaxis strategies across CNS-IPI risk groups in patients with diffuse large B-cell non-hodgkin lymphoma","volume":"7","author":"Faqah","year":"2021","journal-title":"JCO Glob Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109299_b0025","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/bjh.16070","article-title":"Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity","volume":"187","author":"Eyre","year":"2019","journal-title":"Br. J. Haematol."},{"issue":"8","key":"10.1016\/j.intimp.2022.109299_b0030","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41408-021-00535-y","article-title":"High-dose methotrexate is effective for prevention of isolated CNS relapse in diffuse large B cell lymphoma","volume":"11","author":"Ong","year":"2021","journal-title":"Blood Cancer J."},{"issue":"10","key":"10.1016\/j.intimp.2022.109299_b0035","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1093\/annonc\/mdx353","article-title":"Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial","volume":"28","author":"Gleeson","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2022.109299_b0040","doi-asserted-by":"crossref","unstructured":"A.D. Zelenetz, L.I. Gordon, J.E. Chang, B. Christian, J.S. Abramson, R.H. Advani, N.L. Bartlett, L.E. Budde, P.F. Caimi, S. De Vos, B. Dholaria, B. Fakhri, L.E. Fayad, M.J. Glenn, T.M. Habermann, F. Hernandez-Ilizaliturri, E. Hsi, B. Hu, M.S. Kaminski, C.R. Kelsey, N. Khan, S. Krivacic, A.S. LaCasce, M. Lim, M. Narkhede, R. Rabinovitch, P. Ramakrishnan, E. Reid, K.B. Roberts, H. Saeed, S.D. Smith, J. Svoboda, L.J. Swinnen, J. Tuscano, J.M. Vose, M.A. Dwyer, H. Sundar, NCCN guidelines(R) insights: B-cell lymphomas, Version 5.2021, J. Natl. Compr. Canc. Netw. 19 (11) (2021) 1218\u20131230.","DOI":"10.6004\/jnccn.2021.0054"},{"issue":"6","key":"10.1016\/j.intimp.2022.109299_b0045","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41408-021-00506-3","article-title":"Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse","volume":"11","author":"Bobillo","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.intimp.2022.109299_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2017.07.029","article-title":"Anaplastic lymphoma kinase gene rearrangement predicts better prognosis in NSCLC patients: a meta-analysis","volume":"112","author":"Wang","year":"2017","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.intimp.2022.109299_b0055","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/bjc.2014.405","article-title":"A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma","volume":"111","author":"Cheah","year":"2014","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.intimp.2022.109299_b0060","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.lungcan.2014.06.011","article-title":"EGFR mutations and clinical outcomes of chemotherapy for advanced non-small cell lung cancer: a meta-analysis","volume":"85","author":"Zhang","year":"2014","journal-title":"Lung Cancer"},{"issue":"11","key":"10.1016\/j.intimp.2022.109299_b0065","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1002\/cncr.26588","article-title":"Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database","volume":"118","author":"Kumar","year":"2012","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.intimp.2022.109299_b0070","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/bjh.13194","article-title":"Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era","volume":"168","author":"Ferreri","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.intimp.2022.109299_b0075","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/ajh.26181","article-title":"Ineffectiveness of high-dose methotrexate for prevention of CNS relapse in diffuse large B-cell lymphoma","volume":"96","author":"Puckrin","year":"2021","journal-title":"Am. J. Hematol."},{"issue":"8","key":"10.1016\/j.intimp.2022.109299_b0080","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1182\/bloodadvances.2020003947","article-title":"Efficacy and safety of prophylactic high-dose MTX in high-risk DLBCL: a treatment intent-based analysis","volume":"5","author":"Jeong","year":"2021","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.intimp.2022.109299_b0085","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s12185-019-02653-7","article-title":"Systemic HD-MTX for CNS prophylaxis in high-risk DLBCL patients: a prospectively collected, single-center cohort analysis","volume":"110","author":"Lee","year":"2019","journal-title":"Int. J. Hematol."},{"issue":"8","key":"10.1016\/j.intimp.2022.109299_b0090","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1007\/s00277-020-04140-0","article-title":"Impact of central nervous system (CNS) prophylaxis on the incidence of CNS relapse in patients with high-risk diffuse large B cell\/follicular grade 3B lymphoma","volume":"99","author":"Kuitunen","year":"2020","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.intimp.2022.109299_b0095","doi-asserted-by":"crossref","unstructured":"K.L. Lewis, L.H. Jakobsen, D. Villa, S. Bobillo, K.E. Smedby, K.J. Savage, T.A. Eyre, K. Cwynarski, P.L. Caporn, J.V. Zyl, M. Trneny, R. Puckrin, D.A. Stewart, M.J. Bishton, C.P. Fox, A.M. Tun, G.T. Thanarajasingam, F. Djebbari, E. Joffe, S. Eloranta, S. Harrysson, L.H. Sehn, S.M. Maliske, K. Poonsombudlert, X. Guo, G. Hapgood, K. Manos, E. Hawkes, J. Khwaja, A. Minson, M. Dickinson, A.K. \u00d8vlisen, G.P. Gregory, M. Gilbertson, I.T. Streit, H.W. Scott, M. Ku, S. Mel, K.Y. Yong, L. Xin, M. Mokoonlall, D. Talaulikar, N.L. McVilly, A. Johnston, M.J. Brunner, P.A. Pophali, M.J. Maurer, T.C. EI-Galaly, C.Y. Cheah, High-dose methotrexate is not associated with reduction in CNS relapse in patients with aggressive B-cell lymphoma: an international retrospective study of 2300 high-risk patients, Blood 138 (2021) 181\u2013184.","DOI":"10.1182\/blood-2021-146737"},{"issue":"3","key":"10.1016\/j.intimp.2022.109299_b0100","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00277-021-04739-x","article-title":"Optimization of high-dose methotrexate prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma: a multicenter analysis","volume":"101","author":"Fang","year":"2022","journal-title":"Ann. Hematol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109299_b0105","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1182\/blood.2021012888","article-title":"Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions","volume":"139","author":"Orellana-Noia","year":"2022","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.intimp.2022.109299_b0110","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2017.72.7602","article-title":"Primary CNS lymphoma","volume":"35","author":"Grommes","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109299_b0115","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.blre.2011.12.001","article-title":"CNS prophylaxis in diffuse large B-cell lymphoma: if, when, how and for whom?","volume":"26","author":"Siegal","year":"2012","journal-title":"Blood Rev."},{"issue":"11","key":"10.1016\/j.intimp.2022.109299_b0120","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1172\/JCI106181","article-title":"Treatment of leukemia with large doses of methotrexate and folinic acid: clinical-biochemical correlates","volume":"48","author":"Hryniuk","year":"1969","journal-title":"J. Clin. Investig."},{"issue":"16","key":"10.1016\/j.intimp.2022.109299_b0125","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2021014506","article-title":"Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients","volume":"139","author":"Wilson","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.intimp.2022.109299_b0130","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.intimp.2022.109299_b0135","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3109\/10428194.2013.811239","article-title":"Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis","volume":"55","author":"Zhang","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.intimp.2022.109299_b0140","doi-asserted-by":"crossref","unstructured":"L.Y. Law, M. Dutia, R. Stevenson, M. Lau, T. Mok, K. Vu, A.M. Soe, A.R. Lopez, S. Thomas, H.T. Vempaty, A. Gavini, B. Nair, Retrospective review of the safety and efficacy of high-dose methotrexate for prevention of CNS relapse in diffuse large B-cell lymphoma at kaiser permanente- Northern California (Jan 2015 - June 2019), Blood 138 (2021) 4583\u20134584.","DOI":"10.1182\/blood-2021-145144"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922007834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922007834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:51:31Z","timestamp":1761587491000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922007834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":28,"alternative-id":["S1567576922007834"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109299","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prophylaxis strategies containing high dose intravenous methotrexate on preventing CNS relapse for patients with diffuse large B-cell lymphoma at intermediate to high risk: A study based on 12 cohorts in the rituximab era","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109299","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109299"}}